1. Home
  2. CLFD vs AUTL Comparison

CLFD vs AUTL Comparison

Compare CLFD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearfield Inc.

CLFD

Clearfield Inc.

HOLD

Current Price

$30.38

Market Cap

447.2M

Sector

Utilities

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.44

Market Cap

407.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLFD
AUTL
Founded
1979
2014
Country
United States
United Kingdom
Employees
N/A
752
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
447.2M
407.2M
IPO Year
1995
2025

Fundamental Metrics

Financial Performance
Metric
CLFD
AUTL
Price
$30.38
$1.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$43.50
$8.50
AVG Volume (30 Days)
169.2K
1.7M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
31.76
N/A
EPS
N/A
N/A
Revenue
$85,034,000.00
$10,120,000.00
Revenue This Year
$11.64
$80.32
Revenue Next Year
$22.30
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
9.51
496.00
52 Week Low
$23.76
$1.15
52 Week High
$46.76
$2.70

Technical Indicators

Market Signals
Indicator
CLFD
AUTL
Relative Strength Index (RSI) 57.62 46.04
Support Level $28.94 $1.22
Resistance Level $30.99 $1.52
Average True Range (ATR) 1.63 0.08
MACD 0.47 0.01
Stochastic Oscillator 67.44 28.99

Price Performance

Historical Comparison
CLFD
AUTL

About CLFD Clearfield Inc.

Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: